Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Following Exposure to Other B-Cell Maturation Antigen (BCMA)-Targeted Agents
Teclistamab (JNJ-64007957) is a T cell redirecting bispecific antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1 is an open-label, multicohort, phase 1/2 study evaluating teclistamab in patients with relapsed/ refractory multiple myeloma (RRMM) previously treated with ≥3 prior lines of therapy (LOT). An overall response rate (ORR) of 62.0% in patients with no prior anti-BCMA treatment (tx) was previously reported in a pooled analysis from phase 1 and phase 2 cohort A at a median follow-up (MFU) of 7.8 months.
Here, efficacy and safety results of teclistamab from cohort C are reported, which enrolled patients who had prior exposure to anti-BCMA treatment.
Dr. Cyrille Touzeau (University Hospital of Nantes—Nantes, France) reports on the evaluation of teclistamab’s (JNJ-64007957) safety and efficacy in RRMM Patients following exposure to other BCMA-targeted agents.
These preliminary results observed with serial targeting of BCMA with teclistamab following Antibody-drug conjugates (ADC) or CAR T treatment (tx) suggest a promising overall response rate (ORR) with early responses that deepen over time. Additionally, a well-tolerated safety profile was observed in patients treated with anti-BCMA tx.
Doctor Bio:
Dr. Cyrille Touzeau is a hematologist in the Hematology Department from the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment. His PhD was mainly focused on the activity of BH3 mimetics in multiple myeloma. Dr. Touzeau is currently a member of the Intergroupe Francophone du Myélome (IFM). Dr. Touzeau published more than 60 peer‐reviewed publications dedicated to multiple myeloma.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
